1. Home
  2. NTLA vs ASA Comparison

NTLA vs ASA Comparison

Compare NTLA & ASA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$13.03

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

ASA

ASA Gold and Precious Metals Limited

HOLD

Current Price

$74.59

Market Cap

1.4B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTLA
ASA
Founded
2014
1958
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Precious Metals
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.4B
IPO Year
2016
2003

Fundamental Metrics

Financial Performance
Metric
NTLA
ASA
Price
$13.03
$74.59
Analyst Decision
Buy
Analyst Count
18
0
Target Price
$18.34
N/A
AVG Volume (30 Days)
4.0M
168.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
0.08%
EPS Growth
3.14
N/A
EPS
N/A
N/A
Revenue
$57,877,000.00
N/A
Revenue This Year
$1.71
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$1.96
Revenue Growth
59.55
N/A
52 Week Low
$5.90
$23.93
52 Week High
$28.24
$78.21

Technical Indicators

Market Signals
Indicator
NTLA
ASA
Relative Strength Index (RSI) 54.55 60.88
Support Level $10.44 $30.43
Resistance Level $14.61 $78.21
Average True Range (ATR) 0.85 3.20
MACD -0.05 0.16
Stochastic Oscillator 68.14 100.00

Price Performance

Historical Comparison
NTLA
ASA

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About ASA ASA Gold and Precious Metals Limited

ASA Gold And Precious Metals Ltd is a closed-end, non-diversified investment company. Its objective is to provide long-term capital appreciation through investing in companies engaged in the exploration for, development of projects, or mining of precious metals and minerals.

Share on Social Networks: